Seek Returns

IQV vs. RPRX: IQVIA vs. Royalty Pharma Stock Comparison

How do IQVIA (IQV) and Royalty Pharma (RPRX) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

IQVIA (IQV) and Royalty Pharma (RPRX) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but IQV is classified in Life Sciences Tools & Services while RPRX is classified in Pharmaceuticals.

Company profile comparison for IQVIA (IQV) and Royalty Pharma (RPRX)
Profile ItemIQVRPRX
NameIQVIA Holdings Inc.Royalty Pharma plc Class A Ordinary Shares
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & ServicesPharmaceuticals
GICS Sub-IndustryLife Sciences Tools & ServicesPharmaceuticals
Market Capitalization44.80 billion USD38.70 billion USD
CurrencyUSDUSD
ExchangeNYSENasdaq
Listing DateMay 9, 2013June 16, 2020
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

IQV
RPRX
GSPC
Loading price history…
IQVIA (IQV) vs. Royalty Pharma (RPRX), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for IQVIA (IQV) and Royalty Pharma (RPRX). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for IQVIA (IQV) and Royalty Pharma (RPRX). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for IQVIA (IQV) and Royalty Pharma (RPRX)
MetricIQVRPRX
Total Return (1Y)32.11%81.08%
Total Return (3Y, Annualized)13.15%39.21%
Total Return (5Y, Annualized)2.00%14.22%

Risk Profile

Drawdown History

IQV
RPRX
GSPC
Loading price history…
IQVIA (IQV) vs. Royalty Pharma (RPRX), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for IQVIA (IQV) and Royalty Pharma (RPRX). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for IQVIA (IQV) and Royalty Pharma (RPRX)
MetricIQVRPRX
Volatility (1Y, Annualized)40.77%22.05%
Beta (5Y)1.140.36
Max Drawdown (5Y)-51.52%-41.98%
Avg. Volume (3M)1.40M3.10M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
IQV and RPRX are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for IQVIA (IQV) and Royalty Pharma (RPRX)
MetricIQVRPRX
Sharpe Ratio (1Y)0.683.48
Sortino Ratio (1Y)1.035.72

Profitability

ROE (TTM)

Both IQVIA (IQV) at 21.39% and Royalty Pharma (RPRX) at 12.09% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

21.39%

Max
109.18%
IQV
21.39%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

12.09%

Max
109.18%
RPRX
12.09%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
IQVIA (IQV) vs. Royalty Pharma (RPRX): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Royalty Pharma (RPRX) at 25.70% keeps the most of each sales dollar — above its industry’s net margin range — and IQVIA (IQV) at 8.05% also retains a top-quartile share.

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.05%

Max
18.05%
IQV
8.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

25.70%

RPRX
25.70%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
IQVIA (IQV) vs. Royalty Pharma (RPRX): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Royalty Pharma (RPRX) at 81.32% operates in the top operating margin quartile, ahead of IQVIA (IQV) at 13.73%, which runs around its industry’s norm.

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.73%

Max
83.12%
Q3
14.77%
IQV
13.73%
Median
0.00%
Q1
-78.82%
Min
-207.40%

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

81.32%

Max
83.12%
RPRX
81.32%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
IQVIA (IQV) vs. Royalty Pharma (RPRX): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for IQVIA (IQV) and Royalty Pharma (RPRX)
MetricIQVRPRX
ROE (TTM)21.39%12.09%
ROA (TTM)5.08%5.43%
Net Margin (TTM)8.05%25.70%
Operating Margin (TTM)13.73%81.32%
Gross Margin (TTM)33.07%99.79%

Growth

Revenue Growth

Both IQVIA (IQV) at 5.87% and Royalty Pharma (RPRX) at 5.06% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
IQVIA (IQV) vs. Royalty Pharma (RPRX): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both IQVIA (IQV) at 4.67% and Royalty Pharma (RPRX) at 23.09% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Loading chart…
IQVIA (IQV) vs. Royalty Pharma (RPRX): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for IQVIA (IQV) and Royalty Pharma (RPRX)
MetricIQVRPRX
Revenue Growth (YoY)5.87%5.06%
Revenue Growth (3Y CAGR)4.21%2.06%
EPS Growth (YoY)4.67%23.09%
EPS Growth (3Y CAGR)11.08%161.10%

Financial Strength

Current Ratio (MRQ)

Both IQVIA (IQV) at 0.83 and Royalty Pharma (RPRX) at 1.29 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.83

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
IQV
0.83
Min
0.10

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.29

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
RPRX
1.29
Min
0.10
Loading chart…
IQVIA (IQV) vs. Royalty Pharma (RPRX): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both balance sheets lean debt-heavy versus peers, but IQV is more stretched: Royalty Pharma (RPRX) at 0.88 sits in the higher-leverage quartile and IQVIA (IQV) at 2.40 is above its industry benchmark range.

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.40

IQV
2.40
Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.88

Max
1.42
RPRX
0.88
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
IQVIA (IQV) vs. Royalty Pharma (RPRX): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for IQVIA (IQV) and Royalty Pharma (RPRX)
MetricIQVRPRX
Current Ratio (MRQ)0.831.29
Debt / Equity (MRQ)2.400.88
Net Debt / EBITDA4.464.76

Dividends

Dividend Yield (TTM)

IQVIA (IQV) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Royalty Pharma (RPRX) reports a yield of 1.37%, ranking against industry peers normally.

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

IQV
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.37%

RPRX
1.37%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
IQVIA (IQV) vs. Royalty Pharma (RPRX): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

IQVIA (IQV) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Royalty Pharma (RPRX) reports a payout of 60.46%, ranking against industry peers normally.

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

IQV
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

60.46%

RPRX
60.46%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
IQVIA (IQV) vs. Royalty Pharma (RPRX): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for IQVIA (IQV) and Royalty Pharma (RPRX)
MetricIQVRPRX
Dividend Yield (TTM)0.00%1.37%
Dividend Payout Ratio (TTM)0.00%60.46%

Valuation

P/E Ratio (TTM)

IQVIA (IQV) at 33.07 is near its industry’s usual P/E ratio, while Royalty Pharma (RPRX) at 43.99 sits in the richer quartile — RPRX needs stronger growth or earnings quality to justify the premium.

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

33.07

Max
85.34
Q3
43.46
IQV
33.07
Median
26.69
Q1
13.30
Min
0.07

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

43.99

Max
85.34
RPRX
43.99
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
Loading chart…
IQVIA (IQV) vs. Royalty Pharma (RPRX): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

IQVIA (IQV) at 2.59 sits in the cheaper P/S ratio quartile while Royalty Pharma (RPRX) at 14.79 prices around its industry’s middle — IQV costs less per dollar of sales, though read it alongside growth and margins.

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.59

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
IQV
2.59
Min
0.01

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.79

Max
58.18
Q3
25.77
RPRX
14.79
Median
7.30
Q1
3.01
Min
0.01
Loading chart…
IQVIA (IQV) vs. Royalty Pharma (RPRX): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Royalty Pharma (RPRX) at 4.39 is valued about in line with its industry on P/B ratio, while IQVIA (IQV) at 6.73 carries an above-peer premium to book — IQV is pricier on assets.

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.73

Max
13.53
IQV
6.73
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.39

Max
13.53
Q3
6.54
RPRX
4.39
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
IQVIA (IQV) vs. Royalty Pharma (RPRX): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for IQVIA (IQV) and Royalty Pharma (RPRX)
MetricIQVRPRX
P/E Ratio (TTM)33.0743.99
P/S Ratio (TTM)2.5914.79
P/B Ratio (MRQ)6.734.39
Free Cash Flow Yield (TTM)4.72%-1.16%